% | $
Quotes you view appear here for quick access.

Ocean Power Technologies, Inc. Message Board

fearingsf 6 posts  |  Last Activity: Jun 26, 2016 10:53 PM Member since: Jan 11, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • fearingsf fearingsf Jun 26, 2016 10:53 PM Flag

    n biology, explant culture is a technique used for the isolation of cells from a piece or pieces of tissue. Tissue harvested in this manner is called an explant. It can be a portion of the shoot, leaves, or some cells from a plant, or can be any part of the tissue from an animal, or from umblical cord tissue.

  • Hindawi Publishing Corporation
    Stem Cells International
    Volume 2013, Article ID 916837, 10 pages

    Received 20 December 2012; Accepted 19 April 2013
    Academic Editor: Pranela Rameshwar
    Copyright © 2013 Lucio Barile et al. This is an open access article distributed under the Creative Commons Attribution License,
    which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Cardiospheres (CSs) are self-assembling multicellular clusters from the cellular outgrowth from cardiac explants cultured in
    nonadhesive substrates. They contain a core of primitive, proliferating cells, and an outer layer of mesenchymal/stromal cells and
    differentiating cells that express cardiomyocyte proteins and connexin 43. Because CSs contain both primitive cells and committed
    progenitors for the three major cell types present in the heart, that is, cardiomyocytes, endothelial cells, and smooth muscle cells,
    and because they are derived from percutaneous endomyocardial biopsies, they represent an attractive cell source for cardiac
    regeneration. In preclinical studies, CS-derived cells (CDCs) delivered to infarcted hearts resulted in improved cardiac function.
    CDCs have been tested safely in an initial phase-1 clinical trial in patients after myocardial infarction. Whether or not CDCs are
    superior to purified populations, for example, c-kit+ cardiac stem cells, or to gene therapy approaches for cardiac regeneration
    remains to be evaluated.

  • Reply to

    Case of the week 22/2016

    by andy55q Jun 8, 2016 7:42 AM
    fearingsf fearingsf Jun 15, 2016 8:40 PM Flag

    I meant CNAT, not EVOK.

  • Reply to

    Case of the week 22/2016

    by andy55q Jun 8, 2016 7:42 AM
    fearingsf fearingsf Jun 14, 2016 12:37 AM Flag

    EVOK is another effective means available to improve this inflammatory CNS condition!

  • fearingsf by fearingsf Jun 14, 2016 12:35 AM Flag

    hofno2003 • Jun 10, 2016 4:39 AM
    users liked this posts
    users disliked this posts

    This is a very impressive case - because it demonstrated first time that CytoSorb could be used to manage hepatic encephalopathy which is a very serious consequence of terminal liver injury and where are no other effective means available to improve this inflammatory CNS condition!

    Sentiment: Strong Buy

  • Aims

    High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) can modulate glucose metabolism through multiple mechanisms. This study determined the effects of a novel bromodomain and extra-terminal (BET) inhibitor (RVX-208) and putative apoA-I inducer on lipid species contained within HDL (HDL lipidome) and glucose metabolism.
    Materials and methods

    Twenty unmedicated males with prediabetes received 100 mg b.i.d. RVX-208 and placebo for 29–33 days separated by a wash-out period in a randomized, cross-over design trial. Plasma HDL-cholesterol and apoA-I were assessed as well as lipoprotein particle size and distribution using NMR spectroscopy. An oral glucose tolerance test (OGTT) protocol with oral and infused stable isotope tracers was employed to assess postprandial plasma glucose, indices of insulin secretion and insulin sensitivity, glucose kinetics and lipolysis. Whole plasma and HDL lipid profiles were measured using mass spectrometry.

    RVX-208 treatment for 4 weeks increased 6 sphingolipid and 4 phospholipid classes in the HDL lipidome (p ≤ 0.05 versus placebo), but did not change conventional clinical lipid measures. The concentration of medium-sized HDL particles increased by 11% (P = 0.01) and small-sized HDL particles decreased by 10% (P = 0.04) after RVX-208 treatment. In response to a glucose load, after RVX-208 treatment, plasma glucose peaked at a similar level to placebo, but 30 min later with a more sustained elevation (treatment effect, P = 0.003). There was a reduction and delay in total (P = 0.001) and oral (P = 0.003) glucose rates of appearance in plasma and suppression of endogenous glucose production (P = 0.014) after RVX-208 treatment. The rate of glucose disappearance was also lower following RVX-208 (P = 0.016), with no effect on glucose oxidation or total glucose disposal.

    RVX-208 increased 10 lipid classes in the plasma HDL fraction, without altering the concentrations of either apoA-I or HDL-cholesterol (HDL-C). RVX-208 delayed and reduced oral glucose absorption and endogenous glucose production, with plasma glucose maintained via reduced peripheral glucose disposal. If sustained, these effects may protect against the development of type 2 diabetes.

3.3728-0.0872(-2.52%)12:05 PMEDT